Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
73 hedge funds and large institutions have $208M invested in Pear Therapeutics, Inc. Class A Common Stock in 2021 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 1 closing their positions.
5,500% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 1
676% more capital invested
Capital invested by funds: $26.9M → $208M (+$182M)
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
306% more funds holding
Funds holding: 18 → 73 (+55)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Cohanzick Management
Pleasantville,
New York
|
+$13.8M |
| 2 |
RA
RiverPark Advisors
New York
|
+$12.8M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$11.8M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$11.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oribel Capital Management
New York
|
-$13.4K |
| 2 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$1K |
PEAR Hedge Fund Activity: Q2 2021 in Review
73 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q2 2021, worth a combined $208M — up 676% from $26.9M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new PEAR positions and 1 closed out — a net gain of 55 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was Cohanzick Management, opening a new position worth an estimated $13.8M. The largest seller was Oribel Capital Management, cutting an estimated $13.4K.
- 73 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q2 2021, up from 18 in Q1 2021.
- Funds reported $208M of Pear Therapeutics, Inc. Class A Common Stock stock for Q2 2021, up 676% quarter-over-quarter.
- 56 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q2 2021 and 1 closed out, a net change of +55 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q2 2021 was Cohanzick Management, an estimated $13.8M added.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q2 2021 was Oribel Capital Management, an estimated $13.4K sold.
Based on aggregated 13F filings for Q2 2021.